OKYO Pharma reaches milestone with first patient screening for dry eye disease trial
News release
by
OKYO Pharma Ltd
New York
|
May 04, 2023 01:22 PM Eastern Daylight Time
OKYO Pharma Ltd CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED), marking a significant step for the company.
Jacob says the phase II trials aims to evaluate the drug's efficacy and safety in DED patients, with top-line data expected before the end of 2023. If successful, he said the phase II assessment could also serve as one of the two required phase III studies necessary for US Food & Drug Administration (FDA) approval.
Contact Details
Proactive Investors
+1 347-449-0879
